Drugs in MeSH Category Phosphodiesterase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	THEOPHYLLINE	theophylline	TABLET, EXTENDED RELEASE;ORAL	216276-001	Mar 20, 2023	AB	RX	No	No
Schering	THEO-DUR	theophylline	CAPSULE, EXTENDED RELEASE;ORAL	088015-001	Sep 10, 1985		DISCN	No	No
Hospira	AMINOPHYLLINE	aminophylline	INJECTABLE;INJECTION	087601-001	Jul 23, 1982		DISCN	No	No
Panray	AMINOPHYLLINE	aminophylline	TABLET;ORAL	084552-001	Approved Prior to Jan 1, 1982		DISCN	No	No
B Braun	THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019212-001	Nov 7, 1984		DISCN	No	No
Sanofi Aventis Us	SLO-PHYLLIN	theophylline	SYRUP;ORAL	085187-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Intl Medication	AMINOPHYLLINE	aminophylline	INJECTABLE;INJECTION	087868-001	Nov 10, 1983		DISCN	No	No

Market dynamics and patent landscape for phosphodiesterase inhibitors (NLM MeSH)

Last updated: July 5, 2026

Phosphodiesterase (PDE) inhibitors span cardiovascular, pulmonary, neurologic, urologic, and dermatology indications, creating a fragmented IP landscape where exclusivity is driven by (1) active ingredient patents, (2) formulation and delivery IP, (3) method-of-use patents, and (4) device or combination product claims. Market access risk concentrates around patent expirations, Orange Book listing depth for oral generics, and the availability of “design-around” formulations that avoid patented polymorphs, coatings, controlled-release matrices, and patient-selection claims.

Which phosphodiesterase inhibitors have the strongest patent estates in 2026?

Short answer: The strongest estates tend to be those with (a) multiple listed Orange Book patents tied to formulations or specific strengths and (b) ongoing new registrations via line extensions. In practice, the biggest portfolio depth is most often seen in prescription oral agents (cardiopulmonary and ED domains) and in products that have distinct controlled-release platforms.

What determines patent strength for PDE inhibitors?

Patent strength in PDE inhibitors usually maps to:

• Orange Book listing density: number of approved drug–product listings tied to patents per NDA/BLA.
• Claim coverage granularity: claims covering active ingredient + specific formulation attributes (e.g., polymorph, solvate, particle size, coating composition, dissolution profile).
• Line-extension strategy: new strengths, new release profiles, or new combinations that shift the “last-to-expire” clock.
• Method-of-use bottlenecks: claims that restrict specific patient populations, dosing regimens, or endpoints (common in cardiopulmonary and ED).
• Manufacturing process claims: especially for advanced intermediates, crystallization conditions, and scalable purification methods.

How does the patent estate differ by PDE subtype?

• PDE5 inhibitors (ED, pulmonary arterial hypertension): estates frequently include formulation IP and method-of-use claims tied to ED dosing and PAH-directed use. Competitive pressure builds around formulation design-arounds as soon as core patents expire.
• PDE4 inhibitors (inflammation/dermatology, COPD trials historically): often show heavy reliance on method-of-use and formulation stability IP.
• PDE3/other PDE inhibitors (inotropes/heart failure and investigational uses): fewer blockbuster oral products but concentrated IP around salts, intermediates, and dosing formulations.
• PDE10/PDE9/PDE11 (CNS research programs): primarily pre-commercial IP with different timelines and fewer FDA-approved products in the near-term.

How do FDA exclusivity and patent expiration timelines shape PDE inhibitor pricing power?

Short answer: Pricing power typically persists until the later of (1) composition and method-of-use patent expiry and (2) any remaining FDA exclusivity for the NDA/BLA drug product (including 3-year, 5-year new clinical investigations, and 7-year orphan periods when applicable). In PDE inhibitors, the “later date” is frequently pushed by formulation or device-related line extensions.

What are the usual exclusivity failure points for generics?

• Orange Book “listed patents” still block approval: Para IV challenges can only target listed patents; design-around does not help if the generic would infringe other listed patents.
• Method-of-use patents require “carve-outs”: label restrictions can trigger carve-out manufacturing or marketing triggers.
• Controlled-release and coating patents: even when API patents expire, generics can face launch delays from formulation-specific patents.

What timing windows matter for launch planning?

• Patent expiry window: the earliest date any claim expires, not the first filing.
• Last-to-expire listed patent: the functional launch date unless a court eliminates the barrier via an injunction decision or agreement.
• 30-month stay risk (for Paragraph IV filings): affects first generic entry timing even when eligibility is strong.

What patents protect phosphodiesterase inhibitors for erectile dysfunction and pulmonary arterial hypertension?

Short answer: In PDE5 inhibitors, IP commonly clusters into (1) compound and salt form claims for the PDE5 active ingredient; (2) formulation and tablet/capsule release profile claims; and (3) method-of-use claims covering ED dosing schedules and PAH-based patient regimens.

ED domain: typical patent claim clusters

• Active ingredient and salt form: core composition-of-matter claims, plus intermediate and process claims.
• Immediate-release tablet formulation: excipient systems, disintegration behavior, and stability.
• Method-of-use: dose titration schedules, patient response endpoints, and specific age/condition subgroups.

PAH domain: typical patent claim clusters

• Oral PDE5 inhibitors for PAH: formulation patents often dominate around controlled dosing and bioavailability profile.
• Method-of-use: restrictions around WHO functional class, hemodynamic endpoints, and treatment sequencing.

How many patents cover each PDE inhibitor in the Orange Book?

Short answer: Coverage depth varies widely by product line, but the strategic takeaway is that launch risk is rarely driven by a single patent. For PDE inhibitors, the practical barrier is often the number of separately listed patents for the same NDA drug product and the distribution across drug-substance vs drug-product vs method-of-use.

How to interpret “patent count”

• Count alone is not strength: claim scope matters.
• Concentration matters: when multiple patents share the same family core, invalidation of one may not eliminate the rest.
• Staggering line extensions: additional strengths can extend exclusivity even if the first strength expires.

Which companies are challenging phosphodiesterase inhibitor patents with Paragraph IV ANDAs?

Short answer: Paragraph IV challenges in PDE inhibitors typically involve large generic and specialty generics that have a track record in complex Orange Book portfolios, with litigation outcomes shaped by settlement leverage and the ability to preserve non-infringing design choices.

Where generic challenges concentrate

• After formulation and method-of-use patents block first generic entry: challengers target patents that appear most vulnerable (e.g., obviousness over crystalline form or stability data).
• When courts split “product” vs “method” coverage: some challengers carve labeling while others attempt full design-around.

What patent litigation affects phosphodiesterase inhibitors most, and what are typical outcomes?

Short answer: Litigation outcomes generally fall into four buckets: (1) early dismissal on procedural grounds, (2) trial-level invalidity or non-infringement findings, (3) settlement with “carve-out” labeling or agreed launch dates, and (4) injunctions that delay launch pending appeals.

What drives outcomes in PDE inhibitor cases

• Whether the generic product matches formulation specifications: coatings and dissolution profiles can establish infringement or non-infringement quickly.
• Whether method-of-use claims are still valid after Supreme Court and Federal Circuit obviousness standards: attack strategy often targets obviousness from known PDE inhibitor dosing literature.
• Whether patent families have multiple “surviving” patents: settlement often reflects the probability that other listed patents will still block launch.

What settlements or licensing deals commonly arise for PDE inhibitors?

Short answer: Settlement agreements in PDE inhibitors commonly fix an agreed generic launch date, permit limited distribution for certain strengths, or require labeling carve-outs to avoid method-of-use infringement.

Common deal terms for market entry

• Agreed entry date aligned to last-to-expire listed patents.
• Scope limits by strength and dosage form: controlled-release vs immediate-release.
• Labeling restrictions: carve-outs from claimed dosing or patient population.

How does the PDE inhibitor patent landscape differ for generics versus biosimilars?

Short answer: PDE inhibitors are almost entirely small molecules; biosimilar frameworks generally do not apply. The practical “comparability” analogue is whether generics can demonstrate bioequivalence and avoid infringement of formulation and method-of-use claims.

What “biosimilar-style risk” looks like for small molecules

• Regulatory approval is not the only barrier: patents still control market entry.
• Bioequivalence can coexist with infringement: even if FDA approves, courts can block launch.

What formulations are protected for PDE inhibitors, and what design-arounds are most common?

Short answer: Formulation patents frequently cover polymorph/solvate selection, particle size, crystallization method, tablet/coating compositions, and dissolution or release profiles. The most common design-arounds change physical form, processing parameters, and excipient systems to avoid matching claim limitations.

Formulation IP hot spots

• Polymorph and crystal habit: especially for APIs with multiple solid forms.
• Controlled-release matrices: polymers, binders, and release kinetics.
• Film coatings: composition and thickness ranges affecting dissolution.
• Salt selection: when multiple salts exist with distinct stability and hygroscopicity profiles.

Manufacturing-method IP

• Crystallization and drying conditions
• Intermediate synthesis conditions
• Scale-up yield and purification steps

What generic entry risks exist for phosphodiesterase inhibitors after patent expiry?

Short answer: The main risks are that (1) formulation or method-of-use patents survive past the perceived “core” expiry and (2) Orange Book listings extend last-to-expire dates via line extensions. Even when API patents expire, a generic can still be blocked by drug-product or method-of-use patents.

Entry risk matrix for launch planning

• High risk: multiple listed patents across drug-substance, drug-product, and method-of-use; controlled-release or specific polymorph coverage.
• Medium risk: fewer listed patents but meaningful formulation claims.
• Lower risk: single family coverage dominated by composition claims and minimal formulation/method listings.

How does the PDE inhibitor competitive landscape evolve as patents expire?

Short answer: Competitors tend to shift quickly from “patent-dependent” differentiation to manufacturing scale, supply reliability, and label breadth. As a product approaches expiry, generics prioritize launch readiness around the last-to-expire date and court outcomes in ongoing Paragraph IV cases.

Typical post-expiry market structure

• First entrant advantage: early generic or authorized generic can take share quickly when patents fall.
• Second-wave compression: pricing pressure increases with multiple filings and authorized generic use.
• Brand defense via line extensions: reformulations, new strengths, or combination products to reset exclusivity.

What is the Orange Book status of PDE inhibitors and how is it used in litigation?

Short answer: The Orange Book listing is the legal predicate for whether a Paragraph IV challenge can proceed. For PDE inhibitors, the practical process is:

1. identify all listed patents for the NDA drug product,
2. classify them by scope (substance/product/method),
3. build infringement mapping around formulation and label claims,
4. choose attack targets likely to remove the entire barrier.

How litigators structure Orange Book-based cases

• Patent-by-patent claim mapping against the generic label and product specs.
• Non-infringement via manufacturing or labeling constraints.
• Invalidity attacks concentrated on obviousness from prior art PDE inhibitor dosing and formulation literature.

Key Takeaways

• PDE inhibitors have fragmented IP across active ingredients, formulations, and method-of-use claims; the last-to-expire listed patents are the operational launch determinant.
• Orange Book depth and line-extension strategy usually dominate competitive timing over core API patent expiry alone.
• For small-molecule PDE inhibitors, generic entry risk is primarily patent- and formulation-driven, not biosimilar-style interchangeability risk.
• Litigation outcomes and settlement agreements are typically structured around agreed launch dates, strength limitations, and labeling carve-outs tied to method-of-use and formulation coverage.

FAQs

1. Which PDE5 inhibitor has the deepest Orange Book patent coverage for formulations and method of use?
2. How do controlled-release or film-coating patents impact generic substitution timing for PDE inhibitors?
3. What types of prior art most often drive obviousness challenges in PDE inhibitor method-of-use litigation?
4. Do labeling carve-outs meaningfully reduce infringement risk for Paragraph IV generics in PDE inhibitor cases?
5. How do line extensions (new strengths or release profiles) extend exclusivity in PDE inhibitor portfolios?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. Food and Drug Administration. Drug Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman). FDA.
3. U.S. Court of Appeals for the Federal Circuit. Case law on patent infringement, non-infringement, and obviousness relevant to Hatch-Waxman Paragraph IV litigations. Federal Circuit.
4. United States Patent and Trademark Office. Manual of Patent Examining Procedure (MPEP) and guidance on obviousness and claim scope. USPTO.